RxDoctor Payments Data

Lara Durna

Hematology & Oncology · Harbor City, CANPI 1962579706

Payments from drug & device makers

$2,148,802in general payments, 2019–2025

Across 132 payments — averaging $16,279 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$775K
  • Genentech, Inc.$545K
  • AstraZeneca$422K
  • Daiichi Sankyo Inc.$213K
  • Eli Lilly$94K
  • Gilead$39K
  • plus $62K from 4 others
$6,734in research payments, 2019–2025

Across 2 payments — averaging $3366.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

What the payments were for

  • Food & beverage$1250%
  • Education$1250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis8$775,034
Genentech, Inc.67$544,721
AstraZeneca5$421,602
Daiichi Sankyo Inc.9$212,614
Eli Lilly15$94,039
Gilead5$38,577
F. Hoffmann-la Roche AG1$25,000
Seagen Inc.6$23,456
Merck15$13,748
Merge Healthcare Incorporated1$12

How this compares

$2,148,802 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole24$690

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Harbor City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →